<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chutharat Saereewat</style></author><author><style face="normal" font="default" size="100%">Kusuma Sriyakul</style></author><author><style face="normal" font="default" size="100%">Parunkul Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Sunyarn Niempoog</style></author><author><style face="normal" font="default" size="100%">Sucharat Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Chuntida Kamalashiran</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and Safety of Traditional Transdermal Patch (Ya-Pok- Dud-Pid) in Primary Knee Osteoarthritis Patients: A Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Diclofenac</style></keyword><keyword><style  face="normal" font="default" size="100%">Osteoarthritis of knee</style></keyword><keyword><style  face="normal" font="default" size="100%">Traditional</style></keyword><keyword><style  face="normal" font="default" size="100%">Transdermal Patch</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">570-575</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Patients with Knee Osteoarthritis (KOA) have a progressive decline in their social and physical abilities, which affects their quality of life. The Thai Traditional Transdermal Patch (Ya-Pok-Dud- Pid; YP) has been widely used for the treatment of KOA. &lt;strong&gt;Objective:&lt;/strong&gt; To determine the clinical efficacy and safety of YP in comparison with diclofenac gel (DG) for the treatment of KOA.&lt;strong&gt; Methods:&lt;/strong&gt; 74 primary KOA Patients were enrolled and randomly assigned to YP groups or DG groups. The outcomes were assessed the Visual Analog Scale (VAS), Time Up and Go (TUG), Active Knee Flexion (AKF) and Passive Knee Flexion, chair sit and reach, and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). &lt;strong&gt;Results:&lt;/strong&gt; YP and DG significantly improved VAS, TUG, AKF, PKF, chair sit and reach, and WOMAC (p &amp;lt; 0.05). Remarkably, YP experienced the same immediate pain relief after day 1 treatment as DG. The VAS scores of the YP group exhibited a significant reduction from 60±11.06 to 38.92±17.76, while DG decreased VAS score from 61.24±17.84 to 39.19±20.05 (p &amp;lt;0.001). However, there was no significant difference between the two treatment groups. For adverse event, skin reaction (rash, itchy, and dry skin) was noted in the YP group because of the participant receiving YP for an extended period. Altogether, YP has a similar effect to diclofenac gel on pain severity and physical function in patients with knee osteoarthritis. &lt;strong&gt;Conclusion:&lt;/strong&gt; YP is recommended as a natural therapeutic agent with efficacy and safety treatment for knee osteoarthritis.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">570</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Chutharat Saereewat&lt;sup&gt;1&lt;/sup&gt;, Kusuma Sriyakul1, Parunkul Tungsukruthai&lt;sup&gt;1&lt;/sup&gt;, Sunyarn Niempoog&lt;sup&gt;2&lt;/sup&gt;, Sucharat Tungsukruthai&lt;sup&gt;3&lt;/sup&gt;, Chuntida Kamalashiran&lt;sup&gt;1&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Integrative Medicine, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, 12120, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Orthopedic, Thammasat University (Rangsit Campus), Pathum Thani, 12120, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90110, THAILAND.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patnaree Wongmanit</style></author><author><style face="normal" font="default" size="100%">Kusuma Sriyakul</style></author><author><style face="normal" font="default" size="100%">Parunkul Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Ouppatham Supasyndh</style></author><author><style face="normal" font="default" size="100%">Pratya Phetkate</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal Resistive Index and Estimated Glomerular Filtration Rate in Nondiabetic Chronic Kidney Disease Stage 3: A Cross-Sectional Analytical Study</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">538-544</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Renal resistive index (RRI) and estimated glomerular filtration rate (eGFR) are predictive markers for chronic kidney disease (CKD) progression. &lt;strong&gt;Aim:&lt;/strong&gt; To evaluate RRI value, eGFRcr-cys and renal biomarker in nondiabetic patients with CKD stage 3 in Bangkok, Thailand. &lt;strong&gt;Methods:&lt;/strong&gt; A cross-sectional analytical analysis was conducted involving nondiabetic patients with CKD stage 3, aged 35-85 years. Ultrasound was used to assess the RRI of arteries in both kidneys. Patients underwent assessments of serum and urine 24-hour. &lt;strong&gt;Results:&lt;/strong&gt; Among the 61 participants (67.2% male; mean age 69.03 ± 12.59 years), the mean eGFRcr-cys was 41.63 ± 8.64 mL/min/1.73 m², and the mean RRI was 0.65 ± 0.06. Patients were categorized into three RRI groups: low (&amp;lt;0.65, n=35), intermediate (0.65-0.70, n=14), and high (&amp;gt;0.70, n=12). The high RRI group showed a mean RRI of 0.73 ± 0.05 (p &amp;lt; 0.01). Among those with high RRI group were significant decreased right kidney size (p&amp;lt;0.05) and they had a lower BMI, averaging 22.49 ± 3.48. An increase in PP (59.66 ± 13.84, p=0.04) was also significant in this group. The correlations coefficient of RRI value showed a significant positive correlation with age (p&amp;lt;0.05) and significant negative with BMI (p&amp;lt;0.05). In addition, eGFRcr-cys displayed a significant negative correlation with UAGT and 24hUP (p&amp;lt;0.05) and a significant while eGFRcr-cys positive correlation with both kidney size and urine iNOS(p&amp;lt;0.01). &lt;strong&gt;Conclusion:&lt;/strong&gt; An increase in RRI is inversely linked to age, BMI, and PP. Lower eGFR is correlated with factors that cause CKD progression.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">538</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Patnaree Wongmanit&lt;sup&gt;1&lt;/sup&gt;, Kusuma Sriyakul&lt;sup&gt;1&lt;/sup&gt;, Parunkul Tungsukruthai&lt;sup&gt;1&lt;/sup&gt;, Ouppatham Supasyndh&lt;sup&gt;2&lt;/sup&gt;, Sucharat Tungsukruthai&lt;sup&gt;3&lt;/sup&gt;, Pratya Phetkate&lt;sup&gt;1&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Integrative Medicine, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, 12120, THAILAND.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Faculty of Medicine, Kasetsart University, Ngamwongwan Rd, Chatuchak, Bangkok 10900, THAILAND.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90110, THAILAND.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Piracha Jumpa-ngern</style></author><author><style face="normal" font="default" size="100%">Parunkul Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Chuntida Kamalashiran</style></author><author><style face="normal" font="default" size="100%">Somboon Kietinun</style></author><author><style face="normal" font="default" size="100%">Kesara Na- Bangchang</style></author><author><style face="normal" font="default" size="100%">Kusuma Sriyakul</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety Assessment of Oral Lysiphyllum strychnifolium Aqueous Extract in Healthy Volunteers</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Clinical study</style></keyword><keyword><style  face="normal" font="default" size="100%">Healthy volunteers</style></keyword><keyword><style  face="normal" font="default" size="100%">Lysiphyllum strychnifolium</style></keyword><keyword><style  face="normal" font="default" size="100%">Safety</style></keyword><keyword><style  face="normal" font="default" size="100%">Yanang Daeng</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">February 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">235-240</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; &lt;em&gt;Lysiphyllum strychnifolium&lt;/em&gt; (LS), widely known as Ya nang daeng in Thailand, is a traditional herbal remedy that has long been used to promote health and treat diverse health conditions, especially detoxification, by alleviating the severity of symptoms and lowering the risks associated with toxic exposures. Although it is extensively used in Thailand, human safety studies have been lacking. Thus, this study aimed to examine the safety of using LS capsules in healthy participants through a Phase I clinical trial. &lt;strong&gt;Objective:&lt;/strong&gt; This study aimed to investigate the safety of aqueous extract of LS in twenty-four healthy Thai participants. &lt;strong&gt;Method: &lt;/strong&gt;The participants were received 1,000 mg of LS aqueous extract each morning before their meals for seven days. All participants were examined safety assessment including history taking, physical examination, and laboratory tests at day 0, 8 and 14 (follow-up). &lt;strong&gt;Results:&lt;/strong&gt; The findings showed that there were no significant side effects or abnormalities found during the history taking, physical examination, or laboratory evaluation. Particularly, when compared to baseline, participants who received LS experienced statistically significant reductions in blood sugar, triglyceride, LDL cholesterol, and creatinine (P &amp;lt; 0.05), but still within normal ranges. &lt;strong&gt;Conclusions:&lt;/strong&gt; Dietary supplementation with 1,000 mg of LS aqueous extract per day may have a beneficial effect on blood sugar and cholesterol management while remaining safe for healthy people.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">235</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Piracha Jumpa-ngern&lt;sup&gt;1&lt;/sup&gt;, Parunkul Tungsukruthai&lt;sup&gt;1&lt;/sup&gt;, Chuntida Kamalashiran&lt;sup&gt;1&lt;/sup&gt;, Somboon Kietinun&lt;sup&gt;1&lt;/sup&gt;, Kesara Na-Bangchang&lt;sup&gt;2,3&lt;/sup&gt;, Kusuma Sriyakul&lt;sup&gt;1,&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Integrative Medicine, Chulabhorn International College of Medicine, Thammasat University, Pathumthani 12120, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat. University, Pathum Thani 12120, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathumthani 12120, THAILAND.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sucharat Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Runtikan Pochairach</style></author><author><style face="normal" font="default" size="100%">Aungkana Krajarng</style></author><author><style face="normal" font="default" size="100%">Piracha Jumpa-ngern</style></author><author><style face="normal" font="default" size="100%">Parunkul Tungsukruthai</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Investigation of The Network Pharmacology and Mechanism of Action of Centella Asiatica Extract on The Atopic Dermatitis Model</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Atopic dermatitis</style></keyword><keyword><style  face="normal" font="default" size="100%">Centella asiatica</style></keyword><keyword><style  face="normal" font="default" size="100%">Network pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Skin inflammation.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">881-890</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Atopic dermatitis (AD) is a chronic relapsing inflammatory skin condition which has a negative impact on children health. The well-known medicinal plant Centella asiatica extract (CE) is used in herbal skin care products to produce various pharmacological effects in dermatology. However, the molecular target of CE in suppressing inflammatory is largely unknown. &lt;strong&gt;Objective&lt;/strong&gt;: the aim of this study was to examine anti-inflammatory properties and network pharmacology of CE in lipopolysaccharide (LPS)- induced AD &lt;em&gt;in vitro&lt;/em&gt; model.&lt;strong&gt; Method:&lt;/strong&gt; RAW264.7 cells were pre-treated with CE and then were stimulated with LPS and then were investigated cell viability, NO production, and the levels of pro-inflammatory mediators. In addition, the Search Tool for Retrieval of Interacting Genes (STRING), SwissTargetPrediction and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to construct the defined mechanism of action and network pharmacology. &lt;strong&gt;Results:&lt;/strong&gt; CE showed the potent inhibitory effects on LPS-induced NO. In addition, CE significantly suppressed the expression of iNOS and COX-2, as well as the production of IL-2, IL-6, IL-10, and TNF- α. Furthermore, the network pharmacological analysis revealed the potential role of CE in biological processes such as regulating JAK/STATs pathway and inhibiting proinflammatory cytokines both of which were linked to AD pathogenesis. &lt;strong&gt;Conclusion:&lt;/strong&gt; Our findings confirm our hypothesis that CE could be developed as a therapeutic therapy for atopic dermatitis due to its pharmacological action and signaling mechanism in the modulation of allergic skin inflammation.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">881</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Sucharat Tungsukruthai&lt;sup&gt;1&lt;/sup&gt;, Runtikan Pochairach&lt;sup&gt;2&lt;/sup&gt;, Aungkana Krajarng&lt;sup&gt;3&lt;/sup&gt;, Piracha Jumpa-ngern&lt;sup&gt;3&lt;/sup&gt;, Parunkul Tungsukruthai&lt;sup&gt;3,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90110, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Thammasat University Research Unit in Mechanisms of Drug Action and Molecular Imaging, Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathum Thani 12120, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Chulabhorn International College of Medicine Thammasat University, Pathum Thani 12120, THAILAND.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patnaree Wongmanit</style></author><author><style face="normal" font="default" size="100%">Parunkul Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Pratya Phetkate</style></author><author><style face="normal" font="default" size="100%">Daraporn Rungprai</style></author><author><style face="normal" font="default" size="100%">Sucharat Tungsukruthai</style></author><author><style face="normal" font="default" size="100%">Ouppatham Supasyndh</style></author><author><style face="normal" font="default" size="100%">Kusuma Sriyakul</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety Assessment of Supplementation with Cymbopogon citratus Stapf. (Lemongrass) Extract in Patients with Chronic Kidney Disease Stage 3: A Preliminary 90-Days Prospective Study</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chronic Kidney Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">CKD stage 3</style></keyword><keyword><style  face="normal" font="default" size="100%">Cymbopogon citratus Stapf.</style></keyword><keyword><style  face="normal" font="default" size="100%">Lemongrass</style></keyword><keyword><style  face="normal" font="default" size="100%">Safety</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">976-986</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Chronic kidney disease is a major public health issue, and due to resource constraints, many can't access dialysis. &lt;em&gt;C. citratus&lt;/em&gt;, lemongrass is globally prevalent and known to increase urine output without toxicity.&lt;strong&gt; Objective:&lt;/strong&gt; To examine the safety of &lt;em&gt;C. citratus&lt;/em&gt; in patients with CKD stage 3. &lt;strong&gt;Materials and Methods:&lt;/strong&gt; The major compound of &lt;em&gt;C. citratus&lt;/em&gt; was analyzed using high-performance liquid chromatography (HPLC). 64 patients were enrolled and randomly assigned to control or &lt;em&gt;C. citratus&lt;/em&gt; groups. The control group received a placebo, whereas the &lt;em&gt;C. citratus&lt;/em&gt; group received 900 mg of &lt;em&gt;C. citratus&lt;/em&gt; daily for 90 days. All participants were examined BUN, Scr, Cys-C, and eGFR, liver functions, RBC, HCT, Na+, K+, Cl-, and HCO3, and other biochemical parameters. &lt;strong&gt;Results:&lt;/strong&gt; HPLC showed &lt;em&gt;C. citratus&lt;/em&gt; contains of phenolic compounds. Clinically, &lt;em&gt;C. citratus &lt;/em&gt;group had no notable side effects on T-Bil, AST, ALT and ALP. Also, maintained eGFR, SCys-C, K+ and Cl level. The level of blood Na+ was significant increase at day 30 (p &amp;lt; 0.05). The control group had a significant decrease in eGFR and HCO3 levels (p &amp;lt; 0.05) and a significant increase of Cl- and SCys-C. In addition, no statistical differences had found between groups in eGFR, BUN, Cr, Na&lt;sup&gt;+&lt;/sup&gt;, K&lt;sup&gt;+&lt;/sup&gt;, HCO3, PO4, RBC and HCT levels. Throughout the 90 days, no drug allergies or side effects were reported. &lt;strong&gt;Conclusion:&lt;/strong&gt; Dietary supplementation with &lt;em&gt;C. citratus&lt;/em&gt; may have a favorable effect on delaying the course of CKD and is safe to use for patients with CKD stage 3.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">976</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Patnaree Wongmanit&lt;sup&gt;1&lt;/sup&gt;, Parunkul Tungsukruthai&lt;sup&gt;1&lt;/sup&gt;, Pratya Phetkate&lt;sup&gt;1&lt;/sup&gt;, Daraporn Rungprai&lt;sup&gt;2&lt;/sup&gt;, Sucharat Tungsukruthai&lt;sup&gt;3&lt;/sup&gt;, Ouppatham Supasyndh&lt;sup&gt;4&lt;/sup&gt;, Kusuma Sriyakul&lt;sup&gt;1,&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Integrative Medicine, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, 12120, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Faculty of Pharmacy, Silpakorn University (Sanamchandra Palace Campus), Nakhon Pathom, 73000, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90110, THAILAND.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Faculty of Medicine, Kasetsart University, Chatuchak, Bangkok 10900, THAILAND.&lt;/p&gt;
</style></auth-address></record></records></xml>